Join the Pancreatic Cancer group to help and get support from people like you.
Pancreatic Cancer News (Page 2)
Related terms: Cancer, Pancreas, Cancer, Pancreatic, Pancreatic Carcinoma
Metabolic-Bariatric Surgery Tied to Reduced Risk for Pancreatic Cancer in Those With Obesity
WEDNESDAY, Oct. 9, 2024 – For individuals with obesity, metabolic-bariatric surgery (MBS) is associated with a reduced risk for pancreatic cancer, especially among those with type 2 diabetes (T2D),...
Ipsen’s Onivyde Regimen, a Potential New Standard-of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA
PARIS, FRANCE, 13 February 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for Onivyde (...
Lynparza (olaparib) Approved in the US as a First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer
30 December 2019 – AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that Lynparza® (olaparib) has been approved in the US for ...
FDA Approves Onivyde (irinotecan liposome injection) for Advanced Pancreatic Cancer
October 22, 2015 – The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced...
FDA Approves Abraxane for Late-Stage Pancreatic Cancer
September 6, 2013 – The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) to treat patients...
FDA Approves Sutent for Rare Type of Pancreatic Cancer
SILVER SPRING, Md., May 20, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors...
Novartis Gains FDA Approval for Afinitor As First New Treatment in Nearly Three Decades for Patients With Advanced Pancreatic NET
Basel, May 5, 2011 - Novartis announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of progressive neuroendocrine tumors of...